Crystal Structure and Properties of Multicomponent Pharmaceutical Materials

A special issue of Crystals (ISSN 2073-4352). This special issue belongs to the section "Crystal Engineering".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 2262

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemistry, School of Science, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro, Tokyo 152-8551, Japan
Interests: crystallography; structure analysis; pharmaceutical crystals; phase transition
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia
Interests: pharmaceutics; drug polymorphism; pharmaceutical crystal; physicochemical properties; multicomponent crystals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit original research or review articles to this Special Issue that focuses on the “Crystal Structure and Properties of Multicomponent Pharmaceutical Materials”.

Multicomponent crystals of pharmaceutical materials include salts, cocrystals, and hydrates/solvates of active pharmaceutical ingredients (APIs). Recently, more sophisticated multicomponent forms of salt-cocrystals, ionic-cocrystals, and drug-drug salts/cocrystals have attracted much attention. The exploration of multicomponent crystals of pharmaceutical materials continues gaining interest in the pharmaceutical field due to the ability of crystals to modulate a broad range of physicochemical properties of the parent API, such as solubility, dissolution rate, stability, hygroscopicity, tabletability, permeability, and palatability. A crystal structure analysis plays an important role in addressing the key information in rationalizing the change in the physicochemical properties of multicomponent crystals.

This Special Issue on the “Crystal Structure and Properties of Multicomponent Pharmaceutical Materials” aims to highlight theoretical and experimental approaches to screening, structural analyses, physicochemical properties characterization, rationalization structure-property relationships, as well as the application of pharmaceutical multicomponent crystals. We encourage the submission of studies on new crystal structures and a characterization of the physicochemical properties of salts, cocrystals, hydrates/solvates, and their interdisciplinary forms of pharmaceutical multicomponent materials.

Contributions from both the industry and academia are welcome.

Dr. Hidehiro Uekusa
Dr. Yuda Prasetya Nugraha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Crystals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2100 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmaceutical crystals
  • multicomponent crystals
  • salts
  • co-crystals
  • solvates
  • physicochemical properties

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 9946 KiB  
Article
The Co-Crystallization of 4-Halophenylboronic Acid with Aciclovir, Caffeine, Nitrofurazone, Theophylline, and Proline in Function of Weak Interactions
by Ventsislav Dyulgerov, Hristina Sbirkova-Dimitrova, Kostadin Iliev and Boris Shivachev
Crystals 2023, 13(3), 468; https://doi.org/10.3390/cryst13030468 - 9 Mar 2023
Cited by 1 | Viewed by 1667
Abstract
Co-crystallization experiments of 4-halophenylboronic acid with several pharmaceutical compounds (including aciclovir, caffeine, nitrofurazone, and proline) produced several new molecular complexes. The experiments involved varying the solvent and the molar ratio of boronic acid to a pharmaceutical compound (e.g., 1:1, 2:1, 1:2). The screening [...] Read more.
Co-crystallization experiments of 4-halophenylboronic acid with several pharmaceutical compounds (including aciclovir, caffeine, nitrofurazone, and proline) produced several new molecular complexes. The experiments involved varying the solvent and the molar ratio of boronic acid to a pharmaceutical compound (e.g., 1:1, 2:1, 1:2). The screening process for new crystal phases revealed that the formation of the different molecular complexes was strongly influenced by the molar ratio and the presence or absence of water in the solvent. The new molecular crystals were characterized through single crystal X-ray diffraction and differential scanning calorimetry (DSC) analyses. The single crystal analyses of the molecular complexes revealed an unexpected variety in the hydrogen bonding network interactions that can be produced by the –B(OH)2 motif. Full article
Show Figures

Figure 1

Back to TopTop